Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sodium Hyaluronate Gel Versus Lidocaine Cream for Endotracheal Tube Lubrication (SHG vs LC)

18 novembre 2026 aggiornato da: Yi Duan, Beijing Tsinghua Chang Gung Hospital

Superiority of Sodium Hyaluronate Gel Over Lidocaine Cream for Endotracheal Tube Lubrication in Reducing Postoperative Throat Numbness: A Randomized Controlled Trial

This study is a prospective, randomized, single-blind, parallel-group, single-center clinical trial in adults undergoing elective laparoscopic surgery under general anesthesia with endotracheal intubation. It will compare sterile medical sodium hyaluronate gel with lidocaine cream as a lubricant applied to the distal portion and cuff surface of the endotracheal tube. The study aims to evaluate whether sodium hyaluronate gel is superior to lidocaine cream in reducing postoperative throat numbness. The primary outcome is throat numbness assessed using a visual analog scale (VAS) 30 minutes after surgery. Secondary outcomes include throat numbness at other specified time points, coughing during emergence and after the first oral water intake, postoperative sore throat, hoarseness, endotracheal tube cuff pressure, hemodynamic responses during intubation and extubation, satisfaction, and adverse events. A total of 120 participants are planned, with 60 participants in each group.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

120

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adults aged 18 to 65 years, of either sex.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Patients scheduled for elective laparoscopic surgery under general anesthesia with endotracheal intubation.
  • Expected surgical duration of 1 to 4 hours.
  • Able to understand the study and provide written informed consent.

Exclusion Criteria:

  • Patients expected to be transferred to the intensive care unit (ICU) postoperatively.
  • Known or anticipated difficult airway.
  • History of severe respiratory disease, such as asthma or chronic obstructive pulmonary disease.
  • High risk of gastroesophageal reflux or aspiration, including a full stomach or a history of severe gastroesophageal reflux disease.
  • Known allergy to sodium hyaluronate, lidocaine, or any other study-related medication/product.
  • Pre-existing sore throat or hoarseness before surgery.
  • Pregnancy or breastfeeding.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Medical sodium hyaluronate lubricating gel

A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation. The protocol lists medical device registration certificate number

Comparatore attivo: Lidocaine cream

A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Throat numbness intensity
Lasso di tempo: 30 minutes after extubation

Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness.

30 minutes after extubation

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Throat numbness intensity
Lasso di tempo: Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.

Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness.

Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.
Time to first oral water intake and incidence of coughing during the first water intake
Lasso di tempo: From extubation to the first oral water intake, within 24 hours after extubation.

The time from extubation to the first oral water intake will be recorded in minutes. The occurrence of coughing during the first water intake will also be recorded.

From extubation to the first oral water intake, within 24 hours after extubation.
Severity of coughing during emergence from general anesthesia
Lasso di tempo: During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.

Coughing during emergence and extubation will be graded as follows: 0 = no cough; 1 = mild, single cough; 2 = moderate, more than one cough with a duration of less than 5 seconds; 3 = severe, cough lasting more than 5 seconds. Suctioning during emergence will be recorded. No routine suctioning will be performed at extubation or during the first 5 minutes after extubation, unless clinically required.

During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.
Postoperative sore throat severity
Lasso di tempo: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.

Postoperative sore throat severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no sore throat, whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe sore throat.

Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
Postoperative hoarseness severity
Lasso di tempo: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.

Postoperative hoarseness severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no hoarseness , whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe hoarseness .

Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
Endotracheal tube cuff pressure measured in cmH₂O
Lasso di tempo: At 1, 2, and 3 hours after intubation, and immediately before extubation.

Endotracheal tube cuff pressure will be measured using a cuff pressure manometer. The pressure will be recorded in cmH₂O.

At 1, 2, and 3 hours after intubation, and immediately before extubation.
Incidence of hemodynamic abnormalities assessed by heart rate and blood pressure measurements
Lasso di tempo: During tracheal extubation

Heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) will be monitored and recorded. Hemodynamic abnormalities are defined as HR greater than 100 beats/min or less than 60 beats/min; SBP ≥140 mmHg and/or DBP ≥90 mmHg; or a decrease in SBP of more than 20% from baseline.

During tracheal extubation
Anesthesiologists' satisfaction with the assigned endotracheal tube lubricant
Lasso di tempo: Immediately after tracheal intubation.

Anesthesiologists' satisfaction with the assigned lubricant will be evaluated using a 5-point Likert scale, with scores ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction.

Immediately after tracheal intubation.
Patient satisfaction with the anesthesia recovery process
Lasso di tempo: Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.

Patient satisfaction with the anesthesia recovery process will be assessed using a 5-point Likert scale during the PACU stay. Scores range from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater satisfaction.

Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.
Incidence of adverse events associated with the study interventions
Lasso di tempo: From administration of the assigned lubricant until 24 hours after extubation.

The occurrence of adverse events, including allergic reactions, laryngospasm, aspiration, nausea, and vomiting, will be recorded and compared between the two groups.

From administration of the assigned lubricant until 24 hours after extubation.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

4 novembre 2026

Completamento primario (Stimato)

4 marzo 2027

Completamento dello studio (Stimato)

10 marzo 2027

Date di iscrizione allo studio

Primo inviato

3 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

18 novembre 2026

Primo Inserito (Effettivo)

20 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi